Vimseltinib
Generic name: vimseltinib
Brand name: Romvimza
Dosage form: oral capsule (14 mg; 20 mg; 30 mg)
Drug class: Miscellaneous antineoplastics
What is vimseltinib?
Vimseltinib is used in adults to treat giant cell tumor of the tendon sheath (also called tenosynovial giant cell tumor) that is not likely to improve with surgery.
Vimseltinib may also be used for purposes not listed in this medication guide.
Vimseltinib side effects
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Vimseltinib may cause serious side effects. Call your doctor at once if you have:
-
rash; or
-
liver problems--loss of appetite, nausea, vomiting, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Your treatments may be reduced, delayed, or permanently discontinued if you have certain side effects.
Common side effects of vimseltinib may include:
-
abnormal lab tests;
-
swelling around your eyes;
-
tiredness;
-
rash, itching; or
-
swelling in your face, hands, or feet.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Related/similar drugs
Romvimza
Romvimza is used to treat symptomatic tenosynovial giant cell tumor (TGCT) in adults when surgery ...
Turalio
Turalio (pexidartinib) is a kinase inhibitor for the treatment of tenosynovial giant cell tumor ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Accutane
Accutane (isotretinoin) is a form of vitamin A and is used to treat severe nodular acne. Includes ...
Adstiladrin
Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus ...
Amnesteem
Amnesteem is used for acne, acute nonlymphocytic leukemia, granuloma annulare, rosacea
Amtagvi
Amtagvi (lifileucel) is a type of medicine called “tumor-derived autologous T cell immunotherapy” th ...
Anktiva
Anktiva (N-803) is used to treat specific types of bladder cancer. It is FDA-approved to be used ...
Pexidartinib
Pexidartinib systemic is used for tenosynovial giant cell tumor
Warnings
Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.
Before taking this medicine
Tell your doctor if you have or have ever had:
Vimseltinib can harm an unborn baby if the mother or the father is using vimseltinib.
-
If you are a woman, you may need a pregnancy test to make sure you are not pregnant. Use birth control while using this medicine and for at least 1 month after your last dose.
-
If you are a man, use birth control if your sex partner is able to get pregnant. Keep using birth control for at least 1 month after your last dose.
-
Tell your doctor right away if a pregnancy occurs.
Vimseltinib may affect fertility in men or women. Pregnancy could be harder to achieve while either parent is using this medicine.
Do not breastfeed while using this medicine, and for at least 1 month after your last dose.
How should I take vimseltinib?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.
Do not change your dose or stop taking this medicine without your doctor's advice.
Vimseltinib is usually taken twice per week, with at least 72 hours between doses.
You may take vimseltinib with or without food. Follow your doctor's instructions.
Swallow the capsule whole and do not crush, chew, break, or open it.
If you vomit within 30 minutes of taking vimseltinib, take another dose. If you vomit more than 30 minutes of taking vimseltinib, do not take another dose. Take your next dose as scheduled.
You will need frequent blood tests to check your liver function before and during treatment with vimseltinib. Your next dose may be reduced, delayed, or permanently discontinued based on the results.
Your doctor will need to check your progress on a regular basis.
This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using vimseltinib.
Store in the original container at room temperature away from moisture and heat.
Vimseltinib dosing information
Usual Adult Dose for Nodular Tenosynovitis:
30 mg orally twice a week
Comments:
-There should be at least 72 hours between doses, as directed on the blister package.
Use: For treatment of patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
What happens if I miss a dose?
Take the medicine as soon as you can, but skip the missed dose if you are more than 48 hours late for the dose. Do not use two doses at one time.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while taking vimseltinib?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
What other drugs will affect vimseltinib?
Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.
Other drugs may affect vimseltinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
More about vimseltinib
- Check interactions
- Compare alternatives
- Dosage information
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2025 Cerner Multum, Inc. Version: 1.01.